Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study)

Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study)

IMPORTANCE:. Anaphylatoxin C5a, a proinflammatory complement split product, plays a central role in mediating organ dysfunction. OBJECTIVES:. This phase II clinical trial was conducted to study safety, tolerability, pharmacokinetics, and pharmacodynamics of vilobelimab, a recombinant monoclonal anti...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Michael Bauer, MD, Andreas Weyland, MD, Gernot Marx, MD, Frank Bloos, MD, PhD, Stephan Weber, Dipl. Stat., Norbert Weiler, MD, Stefan Kluge, MD, Anja Diers, MD, Tim Philipp Simon, MD, Ingmar Lautenschläger, MD, Matthias Gründling, MD, Ulrich Jaschinski, MD, Philipp Simon, MD, Axel Nierhaus, MD, Onnen Moerer, MD, Lorenz Reill, MD, Achim Jörres, MD, Renfeng Guo, MD, Markus Loeffler, MD, Konrad Reinhart, MD, Niels Riedemann, MD, for the SepNet-Study Group
Format: article
Langue:EN
Publié: Wolters Kluwer 2021
Sujets:
Medical emergencies. Critical care. Intensive care. First aid
RC86-88.9
Accès en ligne:https://doaj.org/article/425409c1c667424ab3c5530f15b92a63
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Documents similaires